[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Gout Epiomic Insights, 2015-2020

November 2015 | 1 pages | ID: GB5DEE599F2EN
Black Swan Analysis limited

US$ 1,055.00

E-mail Delivery (PDF), Hard Copy Mail Delivery

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Epiomic Insights for Gout provides you with a top line snapshot of the market potential in terms of patient populations for this disorder that can deliver inflammatory arthritis and pain to patients. With a growing westernized, sedentary life style, it will be important to quantify potential Gout patients exhibiting severe symptoms in need of more specific or powerful innovative treatments.

Sourcing data from our Epiomic Patient segmentation database, we are able to reference relevant clinical trial data and patient registries to provide a picture of the total projected prevalent population across 8 major global markets.

This one-page synopsis developed by our team of analysts delivers a current overview of the disease and risk factors with a perspective on the future drivers of the patient population. The total Gout population across all markets has been segmented by gender type and estimated glomerular filtration rate status.

This style of report is ideal for companies entering a new market segment or disease area of which they have limited knowledge. Alternatively, companies considering investing in healthcare innovation may benefit from a high-level, accurate overview of the market to determine likely commercial potential of such an investment.


More Publications